Scarica l'app Stockscreener
17.08
21.99%
3.0518
Precedente Chiudi:
$14.03
Aprire:
$15.5
Volume 24 ore:
10.34M
Relative Volume:
5.36
Capitalizzazione di mercato:
$1.50B
Reddito:
-
Utile/perdita netta:
$-95.90M
Rapporto P/E:
-12.94
EPS:
-1.32
Flusso di cassa netto:
$-79.09M
1 W Prestazione:
+99.25%
1M Prestazione:
+107.96%
6M Prestazione:
+389.01%
1 anno Prestazione:
+141.06%
Intervallo 1D:
$15.50
$18.75
Intervallo di 1 settimana:
$7.8691
$18.75
Portata 52W:
$1.865
$18.75
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Nome
Terns Pharmaceuticals Inc
Settore
Industria
Telefono
650-525-5535 EXT.101
Indirizzo
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Confronta TERN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
17.14 | 1.23B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.13 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.77 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.79 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
838.72 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.38 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Ripresa | H.C. Wainwright | Neutral |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2024-10-31 | Iniziato | Oppenheimer | Outperform |
| 2023-06-22 | Iniziato | Mizuho | Buy |
| 2023-06-07 | Iniziato | Jefferies | Buy |
| 2023-05-31 | Iniziato | ROTH MKM | Buy |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-02-07 | Iniziato | UBS | Buy |
| 2022-09-12 | Iniziato | H.C. Wainwright | Neutral |
| 2021-09-14 | Ripresa | Goldman | Buy |
| 2021-03-02 | Iniziato | Cowen | Outperform |
| 2021-03-02 | Iniziato | Goldman | Buy |
| 2021-03-02 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Terns Pharmaceuticals Inc Borsa (TERN) Ultime notizie
Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday - Benzinga
Terns Pharma (TERN) Receives Price Target Raise to $28 by Truist - GuruFocus
Terns Pharmaceuticals stock price target raised to $22 at BMO on strong ASH data - Investing.com Nigeria
Terns Pharmaceuticals stock extends gain after positive CML drug data - Investing.com
Terns Pharmaceuticals stock hits 52-week high at 16.41 USD - Investing.com
Terns Pharma (TERN): Barclays Raises Price Target by 92.86% | TE - GuruFocus
Mizuho Boosts Price Target on Terns Pharmaceuticals to $32 From $9, Keeps Outperform Rating - MarketScreener
Terns reports 64% MMR rate in phase 1 CML trial with TERN-701 - Investing.com Australia
Terns Pharmaceuticals (TERN) Upgraded with Increased Price Targe - GuruFocus
Terns Pharmaceuticals (TERN) Upgraded with Increased Price Target Following Promising Data - GuruFocus
Terns Pharmaceuticals stock rating upgraded to Buy by H.C. Wainwright - Investing.com
Terns Pharma (TERN) Upgraded to Buy by HC Wainwright & Co. | TER - GuruFocus
Terns Pharmaceuticals stock price target raised by Truist on CML drug data - Investing.com South Africa
Price momentum metrics for Terns Pharmaceuticals Inc. explainedEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Relative strength of Terns Pharmaceuticals Inc. in sector analysisMarket Performance Recap & Weekly Return Optimization Alerts - newser.com
Terns Pharmaceuticals (TERN) Is Up 74.1% After Positive Phase 1 TERN-701 Data in CML Patients - Yahoo Finance
Combining price and volume data for Terns Pharmaceuticals Inc.Dollar Strength & Growth Oriented Trade Recommendations - newser.com
How sentiment analysis helps forecast Terns Pharmaceuticals Inc.Quarterly Growth Report & Verified Short-Term Trading Plans - newser.com
Terns Pharmaceuticals (TERN) Pivots After TERN-601 Setback Can a Focus on Oncology Redefine Its Future? - simplywall.st
After GLP-1 drug falters, Terns Pharmaceuticals shifts focus to cancerBizwomen - The Business Journals
Terns Pharma (TERN) Upgraded to Outperform by William Blair | TE - GuruFocus
Oppenheimer raises Terns Pharmaceuticals stock price target to $24 on promising leukemia drug data - Investing.com Australia
William Blair upgrades Terns Pharmaceuticals stock rating to Outperform By Investing.com - Investing.com Australia
Biotech Deals And Breakthroughs Spark Heavy Trading Across Markets - Finimize
Pharmaceutical Stocks To Add to Your WatchlistNovember 3rd - MarketBeat
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades - Benzinga
Terns reports 64% MMR rate in phase 1 CML trial with TERN-701 By Investing.com - Investing.com South Africa
William Blair upgrades Terns Pharmaceuticals stock rating to Outperform - Investing.com
Terns Pharmaceuticals (TERN) Upgraded After Promising Clinical T - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy By Investing.com - Investing.com Philippines
Terns Pharmaceuticals (TERN) Presents Promising Data from CARDINAL Trial - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy - Investing.com
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting - The Manila Times
Terns Pharmaceuticals Announces Positive Data from CARDINAL Trial - TradingView
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML ... - Bluefield Daily Telegraph
Will Terns Pharmaceuticals Inc. stock recover after recent dropPortfolio Return Report & Consistent Profit Trade Alerts - newser.com
Sector ETF performance correlation with Terns Pharmaceuticals Inc.Trade Entry Summary & Low Risk Entry Point Tips - newser.com
Applying Wyckoff theory to Terns Pharmaceuticals Inc. stockMarket Trend Review & High Conviction Buy Zone Picks - newser.com
Should you hold or exit Terns Pharmaceuticals Inc. nowTrade Ideas & Intraday High Probability Setup Alerts - newser.com
Real time breakdown of Terns Pharmaceuticals Inc. stock performanceQuarterly Performance Summary & Target Return Focused Stock Picks - newser.com
How hedge fund analytics apply to Terns Pharmaceuticals Inc. stockWeekly Investment Report & Long-Term Safe Return Strategies - newser.com
Is Terns Pharmaceuticals Inc. still worth holding after the dipJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
How Terns Pharmaceuticals Inc. stock reacts to Fed rate cutsMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Advanced analytics toolkit walkthrough for Terns Pharmaceuticals Inc.Portfolio Value Report & Real-Time Market Trend Scan - newser.com
What Wall Street predicts for Terns Pharmaceuticals Inc. stock priceM&A Rumor & Long-Term Safe Return Strategies - newser.com
What does recent volatility data suggest for Terns Pharmaceuticals Inc.Entry Point & Step-by-Step Swing Trade Plans - newser.com
Terns Pharmaceuticals Inc Stock Analysis and ForecastSwing Trading Watchlist & Today’s Picks, Tomorrow’s Winners - earlytimes.in
Terns Pharmaceuticals Inc Azioni (TERN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
0.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):